Optiver Holding
HRTX icon

Optiver Holding’s Heron Therapeutics HRTX Stock Holding History

Optiver Holding’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$315 Sell
394
-694
-64% -$804 ﹤0.01% 2204
2025
Q4 		$1.41K Sell
1,088
-794
-42% -$980 ﹤0.01% 2137
2025
Q3 		$2.37K Sell
1,882
-1
-0.1% -$2 ﹤0.01% 2317
2025
Q2 		$3.9K Buy
1,883
+1,459
+344% +$2.98K ﹤0.01% 1247
2025
Q1 		$933 Buy
+424
New +$823 ﹤0.01% 1281
2024
Q4 		– Sell
-1,005
Closed -$2K – 1103
2024
Q3 		$2K Sell
1,005
-800
-44% -$1.91K ﹤0.01% 867
2024
Q2 		$6.32K Buy
+1,805
New +$5.54K ﹤0.01% 775

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Optiver Holding's HRTX Position: Q1 2026 in Review

Optiver Holding reduced its Heron Therapeutics (HRTX) stake by 64% in Q1 2026, selling an estimated $804 and leaving 394 shares worth $315. The position accounts for ﹤0.01% of the portfolio, ranked #2204.

Optiver Holding first reported a position in HRTX in Q2 2024 and has held it in 7 quarters since. The position peaked at $6.32K in Q2 2024. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Optiver Holding held 394 shares of Heron Therapeutics worth $315 as of Q1 2026.
  • Optiver Holding sold 694 Heron Therapeutics shares in Q1 2026, an estimated $804.
  • Heron Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q1 2026, its #2204 holding.
  • Optiver Holding first reported a position in Heron Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • Optiver Holding's Heron Therapeutics position peaked at $6.32K in Q2 2024.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Optiver Holding's 13F filing for Q1 2026, filed 15 May 2026.